?
Home
About
Company Overview
History
Group Structure
ESG
Management Team
R&D
Technology Platform
505(b)(2) NDA
High Barrier ANDA
Corporate
Board of Directors
Committee
Internal Audit
Major Internal Policies
Investor
Company Profile
Financials
Shareholders’ Services
Stakeholder
News
Contact
Location
Join Us
Home
About
Company Overview
History
Group Structure
ESG
Management Team
R&D
Technology Platform
505(b)(2) NDA
High Barrier ANDA
Corporate
Board of Directors
Committee
Internal Audit
Major Internal Policies
Investor
Company Profile
Financials
Shareholders’ Services
Stakeholder
News
Contact
Location
Join Us
News
News
Material Information- Announcement of the newly appointed Chief Business Officer
2026-08-06
Material Information- Announcement of the Board’s Resolution to release the non-competition restriction on managerial officers
2026-08-06
Material Information- Announcement of the Board’s Resolution to redeem and cancel treasury shares for a capital reduction and the record date
2026-08-06
Material Information- Announcement on behalf of Handa Pharma, Inc. Increase captial to Handa Oncology, LLC
2026-08-06
Material Information- Announcement of the Board of Directors approved the consolidated financial statements for 2026 Q2.
2026-08-06
Material Information- The Company was invited to attend the in-person and virtual institutional investor conference hosted by First Securities
2026-08-03
Material Information- Announces on Behalf Handa Oncology, LLC, regarding the 505 (b)(2) new formulation drug HND-039 OMCAZIO receives U.S. FDA Tentative Approval (TA)
2026-07-30
Material Information- Announcement of the expected date of the Board Meeting to approve 2026 Q2 Financial Report on August 6, 2026
2026-07-29
Material Information- Correction to Handa Pharmaceuticals, Inc., and on behalf of the subsidiary, regarding the 505(b)(2) new formulation drug HND-039 patent infringement lawsuit
2026-07-15
Material Information- Announces Handa Pharmaceuticals, Inc., and on behalf of the subsidiary, regarding the 505(b)(2) new formulation drug HND-039 patent infringement lawsuit
2026-07-08
1
2
3
4
›
